Search

Your search keyword '"Ho, Vincent T"' showing total 1,596 results
Start Over Author "Ho, Vincent T"
1,596 results on '"Ho, Vincent T"'

301. Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation

Author

Englert, Joshua A., primary, Cho, Michael H., additional, Lamb, Andrew E., additional, Shumyatcher, Maya, additional, Barragan-Bradford, Diana, additional, Basil, Maria C., additional, Higuera, Angelica, additional, Isabelle, Colleen, additional, Vera, Mayra Pinilla, additional, Dieffenbach, Paul B., additional, Fredenburgh, Laura E., additional, Kang, Joyce B., additional, Bhatt, Ami S., additional, Antin, Joseph H., additional, Ho, Vincent T., additional, Soiffer, Robert J., additional, Howrylak, Judie A., additional, Himes, Blanca E., additional, and Baron, Rebecca M., additional

Published
2019
Full Text
View/download PDF

302. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation

Author

Roeker, Lindsey E., primary, Kim, Haesook T., additional, Glotzbecker, Brett, additional, Nageshwar, Prashant, additional, Nikiforow, Sarah, additional, Koreth, John, additional, Armand, Philippe, additional, Cutler, Corey, additional, Alyea, Edwin P., additional, Antin, Joseph H., additional, Richardson, Paul G., additional, Soiffer, Robert J., additional, and Ho, Vincent T., additional

Published
2019
Full Text
View/download PDF

304. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect.

Author

Bachireddy, Pavan, Ennis, Christina, Nguyen, Vinhkhang N., Gohil, Satyen H., Clement, Kendell, Shukla, Sachet A., Forman, Juliet, Barkas, Nikolaos, Freeman, Samuel, Bavli, Natalie, Elagina, Liudmila, Leshchiner, Ignaty, Mohammad, Arman W., Mathewson, Nathan D., Keskin, Derin B., Rassenti, Laura Z., Kipps, Thomas J., Brown, Jennifer R., Getz, Gad, and Ho, Vincent T.

Subjects
CHRONIC lymphocytic leukemia, HEMATOPOIETIC stem cell transplantation, CANCER cell analysis, CANCER stem cells, HLA histocompatibility antigens, HEMATOLOGIC malignancies, LEUKAPHERESIS
Abstract

A tale of two relapses: Allogeneic hematopoietic stem cell transplantation can offer a cure for patients with otherwise incurable hematologic cancers. It is a form of cancer immunotherapy, as the transplanted blood cells from a healthy donor help destroy remaining leukemic cells, a phenomenon called the graft-versus-leukemia effect. Unfortunately, patients can still relapse. To understand the mechanisms involved in such posttransplant relapses, Bachireddy et al. performed detailed genetic analysis of cancer cells from 10 patients with chronic lymphocytic leukemia who relapsed after transplant. The authors found two distinct patterns among these patients: early relapse, caused by preexisting treatment resistance, and late relapse, driven by immune-mediated evolutionary pressure. Leukemic relapse remains a major barrier to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aggressive hematologic malignancies. The basis for relapse of advanced lymphoid malignancies remains incompletely understood and may involve escape from the graft-versus-leukemia (GvL) effect. We hypothesized that for patients with chronic lymphocytic leukemia (CLL) treated with allo-HSCT, leukemic cell–intrinsic features influence transplant outcomes by directing the evolutionary trajectories of CLL cells. Integrated genetic, transcriptomic, and epigenetic analyses of CLL cells from 10 patients revealed that the clinical kinetics of post-HSCT relapse are shaped by distinct molecular dynamics. Early relapses after allo-HSCT exhibited notable genetic stability; single CLL cell transcriptional analysis demonstrated a cellular heterogeneity that was static over time. In contrast, CLL cells relapsing late after allo-HSCT displayed notable genetic evolution and evidence of neoantigen depletion, consistent with marked single-cell transcriptional shifts that were unique to each patient. We observed a greater rate of epigenetic change for late relapses not seen in early relapses or relapses after chemotherapy alone, suggesting that the selection pressures of the GvL bottleneck are unlike those imposed by chemotherapy. No selective advantage for human leukocyte antigen (HLA) loss was observed, even when present in pretransplant subpopulations. Gain of stem cell modules was a common signature associated with leukemia relapse regardless of posttransplant relapse kinetics. These data elucidate the biological pathways that underlie GvL resistance and posttransplant relapse. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

305. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.

Author

Ho, Vincent T., Martin, Andrew St., Pérez, Waleska S., Steinert, Patricia, Zhang, Mei-Jie, Chirnomas, Deborah, Hoang, Caroline J., Loberiza, Fausto R., and Saber, Wael

Subjects
*HEPATIC veno-occlusive disease, *ACUTE myeloid leukemia, *CELL transplantation, *BONE marrow, *TRANSPLANTATION of organs, tissues, etc.
Abstract

• VOD/SOS incidence at 100 days post-HCT was 4% versus 3% in GO-exposed adults versus control subjects. • Five-year overall survival probability was 38% in both groups. • GO exposure before HCT was not associated with an increased risk of VOD/SOS or death. Gemtuzumab ozogamicin (GO) therapy before allogeneic hematopoietic cell transplantation (alloHCT) has been historically associated with an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with acute myeloid leukemia (AML). The current analysis examined VOD/SOS risk and outcomes in a cohort of patients who in recent years were reported to the Center for International Blood and Marrow Transplant Research. Adults with AML who had GO exposure before myeloablative alloHCT were matched 1:4 by age and disease status at transplant to recipients without GO exposure (control subjects). One hundred thirty-seven patients with GO exposure and 548 matched control subjects who underwent alloHCT between 2008 and 2011 were included in this analysis. With a median ∼8-year follow-up of survivors, the 5-year overall survival probability was similar in the 2 cohorts: 38% and 38% in the GO-exposed versus control groups (P =.97). Incidence of VOD/SOS and severe VOD/SOS, respectively, at 100 days was 4% (95% confidence interval [CI], 1% to 7%) and 3% (95% CI, 1% to 6%) in GO-exposed patients and 3% (95% CI, 2% to 5%) and 1% (95% CI, 0% to 2%) in control subjects. Correspondingly, among patients who developed VOD/SOS, 1-year survival probability after VOD/SOS diagnosis was 33% (95% CI, 5% to 72%) and 27% (95% CI, 11% to 47%; P =.78). In multivariate analyses, GO exposure before alloHCT was not associated with an increased risk of VOD/SOS (odds ratio, 1.10; P =.85) or death (hazard ratio, 1.08; P =.57). Three deaths (3%) in the GO group and 3 deaths (<1%) in the control group were attributed to VOD/SOS. Our results suggest that GO treatment before myeloablative alloHCT in the recent era is not associated with an increased risk of post-transplant VOD/SOS or death. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

306. Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets

Author

Cieri, Nicoletta, Hookeri, Nidhi, Stromhaug, Kari, Stevens, Jonathan, Kooshesh, Kameron, Klaeger, Susan, Clauser, Karl R., Sarkizova, Siranush, Braun, David A., Penter, Livius, Oliveira, Giacomo, Kim, Haesook T., Lane, William J., Li, Shuqiang, Livak, Kenneth J., Ho, Vincent T., Ritz, Jerome, Soiffer, Robert J., Keskin, Derin B., Stewart, Chip, Gusev, Alexander, Getz, Gad, and Wu, Catherine J.

Published
2022
Full Text
View/download PDF

307. Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant

Author

Jan, Max, primary, Leventhal, Matt J, additional, Morgan, Elizabeth A, additional, Wengrod, Jordan Chase, additional, Nag, Anewsha, additional, Drinan, Samantha D, additional, Wollison, Bruce M, additional, Ducar, Matthew D., additional, Thorner, Aaron R., additional, Kekre, Natasha, additional, Ho, Vincent T., additional, Koreth, John, additional, Cutler, Corey S., additional, Nikiforow, Sarah, additional, Alyea, Edwin P., additional, Antin, Joseph H., additional, Soiffer, Robert J., additional, Ritz, Jerome, additional, Lindsley, R. Coleman, additional, and Ebert, Benjamin L., additional

Published
2018
Full Text
View/download PDF

308. Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

Author

Lewis, Clinton, primary, Kim, Haesook T., additional, Cutler, Corey S., additional, Koreth, John, additional, Nikiforow, Sarah, additional, Gooptu, Mahasweta, additional, Romee, Rizwan, additional, Glotzbecker, Brett, additional, Nageshwar, Prashant, additional, Alyea, Edwin P., additional, Antin, Joseph H., additional, Richardson, Paul, additional, Soiffer, Robert J., additional, and Ho, Vincent T., additional

Published
2018
Full Text
View/download PDF

309. Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL)

Author

Bachireddy, Pavan, primary, Barkas, Nikolaos, additional, Shukla, Sachet A, additional, Freeman, Samuel, additional, Elagina, Liudmila, additional, Nguyen, Vinhkhang N, additional, Clement, Kendell, additional, Leshchiner, Ignaty, additional, Brown, Jennifer R., additional, Neuberg, Donna S, additional, Ho, Vincent T., additional, Soiffer, Robert J., additional, Ritz, Jerome, additional, Getz, Gad, additional, Alyea, Edwin P., additional, Kharchenko, Peter, additional, and Wu, Catherine J., additional

Published
2018
Full Text
View/download PDF

310. A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Author

Davids, Matthew S., primary, Kim, Haesook T., additional, Costello, Caitlin L., additional, Herrera, Alex F., additional, Locke, Frederick L., additional, Maegawa, Rodrigo O., additional, Savell, Alexandra, additional, Mazzeo, Michael, additional, Avigan, David E., additional, Chen, Yi-Bin, additional, Nikiforow, Sarah, additional, Ho, Vincent T., additional, Cutler, Corey S., additional, Alyea, Edwin P., additional, Bachireddy, Pavan, additional, Wu, Catherine J., additional, Streicher, Howard, additional, Ball, Edward D, additional, Bashey, Asad, additional, Soiffer, Robert J., additional, and Armand, Philippe, additional

Published
2018
Full Text
View/download PDF

311. The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis

Author

Lancman, Guido, primary, Miller, Kathleen, additional, Li, Shuli, additional, Ho, Vincent T., additional, Fathi, Amir T., additional, Chen, Yi-Bin, additional, Keyzner, Alla, additional, Tremblay, Douglas, additional, Geevarghese, Anita, additional, Chatterjee, Prapti, additional, Hoffman, Ronald, additional, Mascarenhas, John, additional, and Hobbs, Gabriela S., additional

Published
2018
Full Text
View/download PDF

312. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Author

Herrera, Alex F., primary, Chen, Lu, additional, Khajavian, Sirin, additional, Chase, Matthew Lewis, additional, Darrah, Justin, additional, Maloney, David G., additional, Ho, Vincent T., additional, Soiffer, Robert J., additional, Antin, Joseph H., additional, Forman, Stephen J, additional, Nademanee, Auayporn P., additional, Chen, Yi-Bin, additional, Armand, Philippe, additional, and Shadman, Mazyar, additional

Published
2018
Full Text
View/download PDF

313. Survival after Hematopoietic Stem Cell Transplantation in an Older, Fit Cohort of Patients with Advanced Myelodysplastic Syndromes: The MDS-TAO Study

Author

Abel, Gregory A., primary, Kim, Haesook T., additional, Steensma, David P., additional, Stone, Richard M., additional, Cronin, Angel M., additional, Habib, Anand R., additional, Ho, Vincent T., additional, Wadleigh, Martha, additional, El-Jawahri, Areej, additional, Alyea, Edwin P., additional, DeAngelo, Daniel J., additional, Koreth, John, additional, Antin, Joseph H., additional, Soiffer, Robert J., additional, and Cutler, Corey S., additional

Published
2018
Full Text
View/download PDF

314. Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd

Author

Kubo, Tomohiro, primary, Romee, Rizwan, additional, Koreth, John, additional, Belizaire, Roger, additional, Kamihara, Yusuke, additional, Liu, Hongye, additional, Asano, Takeru, additional, Whangbo, Jennifer, additional, Hirakawa, Masahiro, additional, Nikiforow, Sarah, additional, Gooptu, Mahasweta, additional, Ho, Vincent T., additional, Cutler, Corey S., additional, Alyea, Edwin P., additional, Antin, Joseph H., additional, Soiffer, Robert J., additional, and Ritz, Jerome, additional

Published
2018
Full Text
View/download PDF

315. 1576. Risk of Clinical Tuberculosis (TB) Among Patients with Latent TB Infection (LTBI) Who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT)

Author

Kusztos, Amanda E, primary, Cheng, Matthew P, additional, Bold, Tyler D, additional, Ho, Vincent T, additional, Glotzbecker, Brett E, additional, Hsieh, Candace, additional, Baker, Meghan A, additional, Hammond, Sarah P, additional, Baden, Lindsey R, additional, and Marty, Francisco M, additional

Published
2018
Full Text
View/download PDF

316. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial

Author

Gooptu, Mahasweta, primary, Kim, Haesook.T., additional, Chen, Yi-Bin, additional, Rybka, Witold, additional, Artz, Andrew, additional, Boyer, Michael, additional, Johnston, Laura, additional, McGuirk, Joseph, additional, Shea, Thomas C., additional, Jagasia, Madan, additional, Shaughnessy, Paul J., additional, Reynolds, Carol G., additional, Fields, Marie, additional, Alyea, Edwin P., additional, Ho, Vincent. T., additional, Glavin, Frank, additional, Dipersio, John F., additional, Westervelt, Peter, additional, Ritz, Jerome, additional, and Soiffer, Robert J., additional

Published
2018
Full Text
View/download PDF

317. Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation

Author

Postalcioglu, Merve, primary, Kim, Haesook T., additional, Obut, Faruk, additional, Yilmam, Osman Arif, additional, Yang, Jiqiao, additional, Byun, Benjamin C., additional, Kupiec-Weglinski, Sophie, additional, Soiffer, Robert, additional, Ritz, Jerome, additional, Antin, Joseph H., additional, Alyea, Edwin, additional, Koreth, John, additional, Cutler, Corey, additional, Armand, Philippe, additional, Paik, Julie M., additional, Leaf, David E., additional, Ho, Vincent T., additional, and Abdi, Reza, additional

Published
2018
Full Text
View/download PDF

319. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis

Author

Gooptu, Mahasweta, primary, Kim, Haesook T., additional, Ho, Vincent T., additional, Alyea, Edwin P., additional, Koreth, John, additional, Armand, Philippe, additional, Ritz, Jerome, additional, Nikiforow, Sarah, additional, Glotzbecker, Brett E., additional, Nageshwar, Prashant, additional, Soiffer, Robert J., additional, Antin, Joseph H., additional, and Cutler, Corey S., additional

Published
2018
Full Text
View/download PDF

320. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Author

Nahas, Myrna R., primary, Soiffer, Robert J., additional, Kim, Haesook T., additional, Alyea, Edwin P., additional, Arnason, Jon, additional, Joyce, Robin, additional, Antin, Joseph H., additional, Ho, Vincent T., additional, Stroopinsky, Dina, additional, Li, Shuli, additional, Levine, James D., additional, McMasters, Malgorzata, additional, Jain, Salvia, additional, Hamdan, Ayad, additional, Tzachanis, Dimitrios, additional, Bryant, Mary Paty, additional, Logan, Emma K., additional, Bazemore, Josie, additional, Stewart, Jeremy, additional, Joyce, Amy, additional, Stephenson, Susan, additional, Washington, Abigail, additional, Cole, Leandra, additional, Pyzer, Athalia, additional, Leaf, Rebecca Karp, additional, Avigan, David E., additional, and Rosenblatt, Jacalyn, additional

Published
2018
Full Text
View/download PDF

322. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome

Author

Kernan, Nancy A., primary, Grupp, Stephan, additional, Smith, Angela R., additional, Arai, Sally, additional, Triplett, Brandon, additional, Antin, Joseph H., additional, Lehmann, Leslie, additional, Shore, Tsiporah, additional, Ho, Vincent T., additional, Bunin, Nancy, additional, Iacobelli, Massimo, additional, Liang, Wei, additional, Hume, Robin, additional, Tappe, William, additional, Soiffer, Robert, additional, and Richardson, Paul, additional

Published
2018
Full Text
View/download PDF

326. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Author

Chen, Evan C., Li, Shuli, Eisfeld, Ann-Kathrin, Luskin, Marlise R., Mims, Alice, Jones, Daniel, Antin, Joseph H., Cutler, Corey S., Koreth, John, Ho, Vincent T., Gooptu, Mahasweta, Romee, Rizwan, El-Jawahri, Areej, McAfee, Steven L., DeFilipp, Zachariah, Soiffer, Robert J., Chen, Yi-Bin, and Fathi, Amir T.

Abstract

Disease relapse after hematopoietic cell transplantation (HCT) is a major cause of treatment failure for patients with acute myeloid leukemia (AML). Maintenance therapy after HCT for patients with targetable mutations such as mutated IDH1or IDH2may improve outcomes, and clinical trials evaluating this strategy are ongoing. However, clinical outcomes of IDH1- and IDH2-mutated AML patients after HCT have not been well described. The primary objective of this study was to describe the clinical characteristics and post-HCT outcomes of IDH-mutated AML patients. Survival outcomes included progression-free survival (PFS), overall survival, and cumulative incidences of relapse and nonrelapse mortality. In this multicenter retrospective analysis, 112 adult patients with IDH1- or IDH2-mutated AML who underwent HCT and did not receive an IDH inhibitor as maintenance therapy after HCT were identified at Massachusetts General Hospital, Dana Farber Cancer Institute, and Ohio State University. Mutation testing was performed using next-generation sequencing panels. Patient characteristics were collected retrospectively, and their survival outcomes were analyzed. Univariate and multivariate analyses were performed. The median patient age was 64.1 years. The median follow-up was 27.5 months. Among patients, 78.5% had intermediate- or adverse-risk disease by European LeukemiaNET criteria. Fifty-eight percent of patients received intensive induction chemotherapy, 82% of patients underwent HCT during first complete remission (CR) or CR with incomplete hematologic recovery (CRi), and 34% of patients received myeloablative conditioning. Frequently detected co-mutations were DNMT3A(35.7%), NPM1(33.1%), and FLT3-ITD(13.4%); TP53mutations were detected in 3.6% of patients. For IDH1-mutated patients transplanted during first CR/CRi, the 1- and 2-year PFS was 75% and 58%, respectively. For IDH2-mutated patients transplanted in first CR/CRi, the 1- and 2-year PFS was 64% and 58%, respectively. The 2-year cumulative incidence of relapse was 31% and 25% for IDH1- and IDH2-mutated cohorts, respectively. Multivariable analysis suggested first CR/CRi and age ≤60 was associated with improved outcomes for IDH2-mutated patients. To date, this is the largest multicenter study of outcomes of IDH-mutated AML patients after HCT. Our analysis provides important benchmarks for analysis and interpretation of results emerging from clinical trials evaluating maintenance IDH1 and IDH2 inhibitor therapy for AML patients after HCT.

Published
2021
Full Text
View/download PDF

327. Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease

Author

Luo, Zhonghui K., Domenech-Estarellas, Edgar A., Han, Amy, Lee, Do, Khatri, Ram, Wahl, Jonathan L., Cutler, Corey, Armand, Philippe, Antin, Joseph H., Koreth, John, Gooptu, Mahasweta, Alyea, Edwin P., Soiffer, Robert J., and Ho, Vincent T.

Abstract

•Forehead application of 1% progesterone gel alleviates signs and symptoms of ocular graft-versus-host disease within 10 weeks.•Improvements occur in the context of stable systemic immunosuppression.•Symptom improvement starts as soon as 30 minutes after the first application.•A novel neurodelivery mechanism may mediate the therapeutic effects.

Published
2021
Full Text
View/download PDF

328. Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

Author

Abel, Gregory A., Kim, Haesook T., Hantel, Andrew, Steensma, David P., Stone, Richard, Habib, Anand, Ho, Vincent T., Wadleigh, Martha, El-Jawahri, Areej, Alyea, Edwin P., DeAngelo, Daniel J., Koreth, John, Antin, Joseph H., Soiffer, Robert J., and Cutler, Corey

Abstract

We conducted a prospective observational study of fit adults aged 60–75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics, or therapy-related MDS) or standard risk with severe cytopenia. A total of 290 patients enrolled at two centers: 175 for adverse risk and 115 for standard risk with severe cytopenia. 113 underwent HCT after a median of 5 months; median follow-up for all was 39.5 months. In univariable analyses, the hazard ratio (HR) for death comparing HCT with no HCT was 0.84 (p= 0.30). The HR for death was 0.64 (p= 0.04) for HCT ≤ 5 months after enrollment and 1.20 (p= 0.39) for HCT > 5 months. In multivariable analyses controlling for age, gender, ECOG performance status, cytogenetic risk, and IPSS risk group, HR for death was 0.75 (p= 0.13) for HCT compared to no HCT, 0.57 (p= 0.01) for adverse MDS risk and 1.33 (p= 0.36) for standard risk with severe cytopenia. In this large, prospective cohort of fit older adults with advanced MDS, we found that survival was significantly improved if HCT was performed early or for adverse risk disease but not for standard risk disease with severe cytopenia.

Published
2021
Full Text
View/download PDF

329. 90Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma

Author

Abou-Nassar, Karim E., Stevenson, Kristen E., Antin, Joseph H., McDermott, Kathleen, Ho, Vincent T., Cutler, Corey S., LaCasce, Ann S., Jacobsen, Eric D., Fisher, David C., Soiffer, Robert J., Alyea, Edwin P., Koreth, John, and Freedman, Arnold S.

Subjects
Adult, Male, Transplantation Conditioning, Incidence, Hematopoietic Stem Cell Transplantation, 90Y-ibritumomab tiuxetan, Antibodies, Monoclonal, Graft vs Host Disease, Radioimmunotherapy, Middle Aged, Article, Disease-Free Survival, Follicular lymphoma, Survival Rate, surgical procedures, operative, hemic and lymphatic diseases, Allogeneic hematopoietic stem cell transplantation, Chronic Disease, Humans, Transplantation, Homologous, Female, Lymphoma, Follicular, Aged, Follow-Up Studies, Retrospective Studies
Abstract

Reduced-intensity conditioning (RIC) hematopoietic SCT (HSCT) is a potentially curative therapeutic option for patients with advanced follicular lymphoma (FL), but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered before RIC allo-HSCT may enhance cytoreduction and allow more time for GVL effect to develop without the associated toxicity of a myeloablative HSCT. We performed a retrospective study to describe the outcomes of patients with relapsed, refractory or transformed FL who received yttrium-90 ((90)Y)-ibritumomab tiuxetan followed by fludarabine and low-dose BU RIC allogeneic HSCT at the Dana-Farber Cancer Institute between 2006 and 2009, inclusively. Twelve patients were identified with a median age of 55 (40-66) years and a median number of lines of therapy of 5 (2-10). Two patients (17%) had transformed to a more aggressive histology and five (42%) had chemorefractory FL. Cumulative incidences of grade II-IV acute GVHD at 100 days were 17% (±11%) and chronic GVHD at 12 months were 63% (±19%). Two-year non-relapse mortality was 18% (±12%). Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies.

Published
2011

330. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease

Author

Magenau, John M., primary, Goldstein, Steven C., additional, Peltier, Dan, additional, Soiffer, Robert J., additional, Braun, Thomas, additional, Pawarode, Attaphol, additional, Riwes, Mary M., additional, Kennel, Maggi, additional, Antin, Joseph H., additional, Cutler, Corey S., additional, Ho, Vincent T., additional, Alyea, Edwin P., additional, Parkin, Brian L., additional, Yanik, Gregory A., additional, Choi, Sung Won, additional, Lewis, Eli C., additional, Dinarello, Charles A., additional, Koreth, John, additional, and Reddy, Pavan, additional

Published
2018
Full Text
View/download PDF

331. Prediction of Severe Acute Graft-Versus-Host Disease (GVHD) in Recipients of HLA Identical Hematopoietic Cell Transplantation (HCT) Using Donor Gene Expression Profiling

Author

Lachance, Silvy, primary, Séguin, Jonathan, additional, Brasey, Ann, additional, Laverdure, Jean-Philippe, additional, Ho, Vincent T., additional, Ritz, Jerome, additional, Storek, Jan, additional, Roy, Denis-Claude, additional, Busque, Lambert, additional, Lemieux, Sébastien, additional, and Perreault, Claude, additional

Published
2018
Full Text
View/download PDF

332. Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids as Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease

Author

Kekre, Natasha, primary, Kim, Haesook T., additional, Ho, Vincent T., additional, Guo, Yikun, additional, Mahmood, Umair, additional, Belatreche, Wafae, additional, Koreth, John, additional, Armand, Philippe, additional, Nikiforow, Sarah, additional, Alyea, Edwin P., additional, Nageshwar, Prashant, additional, Glotzbecker, Brett, additional, El-Jawahri, Areej R., additional, Soiffer, Robert J., additional, Antin, Joseph H., additional, Chen, Yi-Bin, additional, and Cutler, Corey, additional

Published
2018
Full Text
View/download PDF

333. Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)

Author

Ho, Vincent T., primary, Martin, Andrew St, additional, Perez, Waleska, additional, Steinert, Patricia, additional, Zhang, Mei-Jie, additional, Chirnomas, Deborah, additional, Hoang, Caroline J., additional, Loberiza, Fausto R., additional, and Saber, Wael, additional

Published
2018
Full Text
View/download PDF

335. Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials

Author

Holtan, Shernan G., primary, Defor, Todd E., additional, Howard, Alan, additional, Pidala, Joseph A., additional, Levine, John E., additional, Wu, Juan Maggie, additional, Khera, Nandita, additional, Lee, Stephanie J., additional, Bolaños-Meade, Javier, additional, Ho, Vincent T., additional, Alousi, Amin M., additional, Inamoto, Yoshihiro, additional, Chen, George L., additional, Arora, Mukta, additional, Palmer, Jeanne, additional, Flowers, Mary E., additional, Cutler, Corey, additional, Renteria, Anne S., additional, Lukez, Alexander, additional, Arai, Sally, additional, Lazaryan, Aleksandr, additional, Hogan, William J., additional, Newell, Laura F., additional, Jagasia, Madan, additional, Wood, William A., additional, Krupski, M. Christa, additional, Yanik, Gregory A., additional, Bunworasate, Udomsak, additional, Hexner, Elizabeth O., additional, Ayuk, Francis, additional, Holler, Ernst, additional, Mayer, Sebastian, additional, Pusic, Iskra, additional, Duong, Hien K., additional, Efebera, Yvonne A., additional, Ferrara, James, additional, Blazar, Bruce R., additional, Mortari, Angela, additional, Weisdorf, Daniel J., additional, and MacMillan, Margaret L., additional

Published
2018
Full Text
View/download PDF

336. Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells (cTFR) and Suppresses Circulating T Follicular Helper Cells (cTFH) in Patients with Chronic Gvhd

Author

Kamihara, Yusuke, primary, Forcade, Edouard, additional, Koreth, John, additional, Kim, Haesook T., additional, Liu, Hongue, additional, Douchet, Isabelle, additional, Kubo, Tomohiro, additional, Whangbo, Jennifer, additional, Hirakawa, Masahiro, additional, Nikiforow, Sarah, additional, Ho, Vincent T., additional, Armand, Philippe, additional, Cutler, Corey, additional, Alyea, Edwin P., additional, Blanco, Patrick, additional, Blazar, Bruce R., additional, Antin, Joseph H., additional, Soiffer, Robert J., additional, and Ritz, Jerome, additional

Published
2018
Full Text
View/download PDF

337. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma

Author

Herrera, Alex F., primary, Rodig, Scott J., additional, Song, Joo Y., additional, Kim, Young, additional, Griffin, Gabriel K., additional, Yang, Dongyun, additional, Nikolaenko, Liana, additional, Mei, Matthew, additional, Bedell, Victoria, additional, Dal Cin, Paola, additional, Pak, Christine, additional, Alyea, Edwin P., additional, Budde, Lihua E., additional, Chen, Robert, additional, Chen, Yi-Bin, additional, Chan, Wing C., additional, Cutler, Corey S., additional, Ho, Vincent T., additional, Koreth, John, additional, Krishnan, Amrita, additional, Murata-Collins, Joyce L., additional, Nikiforow, Sarah, additional, Palmer, Joycelynne, additional, Pihan, German A., additional, Pillai, Raju, additional, Popplewell, Leslie, additional, Rosen, Steven T., additional, Siddiqi, Tanya, additional, Sohani, Aliyah R., additional, Zain, Jasmine, additional, Kwak, Larry W., additional, Weisenburger, Dennis D., additional, Weinstock, David M., additional, Soiffer, Robert J., additional, Antin, Joseph H., additional, Forman, Stephen J., additional, Nademanee, Auayporn P., additional, and Armand, Philippe, additional

Published
2018
Full Text
View/download PDF

339. Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

Author

Whangbo, Jennifer Sung, primary, Kim, Haesook T., additional, Nikiforow, Sarah, additional, Koreth, John, additional, Kim, Soomin, additional, Alyea, Edwin P., additional, Armand, Philippe, additional, Cutler, Corey, additional, Ho, Vincent T., additional, Antin, Joseph H., additional, Soiffer, Robert J., additional, and Ritz, Jerome, additional

Published
2018
Full Text
View/download PDF

340. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

Author

Koreth, John, primary, Kim, Haesook T., additional, Lange, Paulina B., additional, Poryanda, Samuel J., additional, Reynolds, Carol G., additional, Rai, Sharmila Chamling, additional, Armand, Philippe, additional, Cutler, Corey S., additional, Ho, Vincent T., additional, Glotzbecker, Brett, additional, Yusuf, Rushdia, additional, Nikiforow, Sarah, additional, Chen, Yi-Bin, additional, Dey, Bimalangshu, additional, McMasters, Malgorzata, additional, Ritz, Jerome, additional, Blazar, Bruce R., additional, Soiffer, Robert J., additional, Antin, Joseph H., additional, and Alyea, Edwin P., additional

Published
2018
Full Text
View/download PDF

342. Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease

Author

Wang, Kathy S., primary, Kim, Haesook T., additional, Nikiforow, Sarah, additional, Heubeck, Alexander T., additional, Ho, Vincent T., additional, Koreth, John, additional, Alyea, Edwin P., additional, Armand, Philippe, additional, Blazar, Bruce R., additional, Soiffer, Robert J., additional, Antin, Joseph H., additional, Cutler, Corey S., additional, and Ritz, Jerome, additional

Published
2017
Full Text
View/download PDF

343. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

Author

Soiffer, Robert J., primary, Kim, Haesook T., additional, McGuirk, Joseph, additional, Horwitz, Mitchell E., additional, Johnston, Laura, additional, Patnaik, Mrinal M., additional, Rybka, Witold, additional, Artz, Andrew, additional, Porter, David L., additional, Shea, Thomas C., additional, Boyer, Michael W., additional, Maziarz, Richard T., additional, Shaughnessy, Paul J., additional, Gergis, Usama, additional, Safah, Hana, additional, Reshef, Ran, additional, DiPersio, John F., additional, Stiff, Patrick J., additional, Vusirikala, Madhuri, additional, Szer, Jeff, additional, Holter, Jennifer, additional, Levine, James D., additional, Martin, Paul J., additional, Pidala, Joseph A., additional, Lewis, Ian D., additional, Ho, Vincent T., additional, Alyea, Edwin P., additional, Ritz, Jerome, additional, Glavin, Frank, additional, Westervelt, Peter, additional, Jagasia, Madan H., additional, and Chen, Yi-Bin, additional

Published
2017
Full Text
View/download PDF

344. Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Author

Holtan, Shernan G., primary, DeFor, Todd E., additional, Pidala, Joseph, additional, Khera, Nandita, additional, Lee, Stephanie J., additional, Howard, Alan, additional, Wu, Juan, additional, Bolanos-Meade, F Javier, additional, Ho, Vincent T, additional, Alousi, Amin M., additional, Inamoto, Yoshihiri, additional, Chen, George, additional, Arora, Mukta, additional, Palmer, Jeanne, additional, Flowers, Mary E., additional, Cutler, Corey S., additional, Lukez, Alexander, additional, Arai, Sally, additional, Lazaryan, Aleksandr, additional, Newell, Laura F., additional, Jagasia, Madan, additional, Pusic, Iskra, additional, Mayer, Sebastian A., additional, Wood, William A., additional, Renteria, Anne, additional, Hogan, William J., additional, Hexner, Elizabeth, additional, Ayuk, Francis A, additional, Holler, Ernst, additional, Efebera, Yvonne A, additional, Reantragoon, Rangsima, additional, Duong, Hien, additional, Yanik, Gregory, additional, Ferrara, James L, additional, Levine, John E, additional, Blazar, Bruce, additional, Panoskaltsis-Mortari, Angela, additional, Weisdorf, Daniel J., additional, and MacMillan, Margaret L., additional

Published
2017
Full Text
View/download PDF

345. Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd

Author

Kamihara, Yusuke, primary, Forcade, Edouard, additional, Koreth, John, additional, Liu, Hongye, additional, Kubo, Tomohiro, additional, Whangbo, Jennifer, additional, Hirakawa, Masahiro, additional, Nikiforow, Sarah, additional, Ho, Vincent T, additional, Armand, Philippe, additional, Cutler, Corey S., additional, Alyea, Edwin, additional, Blazar, Bruce, additional, Antin, Joseph H., additional, Soiffer, Robert J., additional, and Ritz, Jerome, additional

Published
2017
Full Text
View/download PDF

346. Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT

Author

Ho, Vincent T., primary, Kim, Haesook T., additional, Bavli, Natalie, additional, Mihm, Martin, additional, Pozdnyakova, Olga, additional, Piesche, Matthias, additional, Daley, Heather, additional, Reynolds, Carol, additional, Souders, Nicholas C., additional, Cutler, Corey, additional, Koreth, John, additional, Alyea, Edwin P., additional, Antin, Joseph H., additional, Ritz, Jerome, additional, Dranoff, Glenn, additional, and Soiffer, Robert J., additional

Published
2017
Full Text
View/download PDF

347. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD

Author

Poe, Jonathan C., primary, Jia, Wei, additional, Su, Hsuan, additional, Anand, Sarah, additional, Rose, Jeremy J., additional, Tata, Prasanthi V., additional, Suthers, Amy N., additional, Jones, Corbin D., additional, Kuan, Pei Fen, additional, Vincent, Benjamin G., additional, Serody, Jonathan S., additional, Horwitz, Mitchell E., additional, Ho, Vincent T., additional, Pavletic, Steven Z., additional, Hakim, Frances T., additional, Owzar, Kouros, additional, Zhang, Dadong, additional, Blazar, Bruce R., additional, Siebel, Christian W., additional, Chao, Nelson J., additional, Maillard, Ivan, additional, and Sarantopoulos, Stefanie, additional

Published
2017
Full Text
View/download PDF

350. ORAL HEALTH STATUS AND RISK OF BACTEREMIA IN PATIENTS UNDERGOING MYELOABLATIVE OGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Author

SULTAN, AHMED S., primary, ZIMERING, YVETTE, additional, PETRUZZIELLO, GLORIA, additional, ALYEA, EDWIN P., additional, ANTIN, JOSEPH H., additional, SOIFFER, ROBERT J., additional, HO, VINCENT T., additional, SONIS, STEPHEN T., additional, WOO, SOOK-BIN, additional, MARTY, FRANCISCO M., additional, and TREISTER, NATHANIEL S., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results